Panbela Therapeutics, Inc. stock is down -35.35% since 30 days ago. The next earnings date is Mar 14, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 8 December’s closed higher than November.
Panbela Therapeutics, Inc. focuses on developing disruptive therapeutics for the treatment of patients with cancer. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for metastatic pancreatic ductal adenocarcinoma.